Predict your next investment

Retinai company logo

See what CB Insights has to offer

Founded Year



Biz Plan Competition - II | Alive

Total Raised


About Retinai

Retinai supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence. Its vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as age-related Macular Degeneration, Diabetic Retinopathy, and Glaucoma. Its solutions rely on advances in medical image analysis, opthalmology, and machine learning.

Retinai Headquarter Location

3 Freiurgstrasse

Bern, 3010,


Latest Retinai News

RetinAI collaborates with Novartis to provide AI solutions for ophthalmology projects

Dec 10, 2020

Dec 10 2020 RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area. Related Stories The first project under the new Master Agreement will support a multi-center international clinical study involving patients with neovascular age-related macular degeneration (nAMD). The study is designed to investigate the influence of optical coherence tomography (OCT) image solutions using Artificial Intelligence (AI) on the assessment of disease activity. The study will be conducted in several clinical centers in numerous European countries and Canada, involving more than 500 patients. For this study, RetinAI will provide its CE-marked web-based software platform, RetinAI Discovery®, a data management platform to efficiently process data at scale across imaging platforms and devices. Discovery® is used today by professionals to navigate imaging data, compute imaging biomarkers and track changes over time for some of the most common forms of eye diseases. RetinAI’s tools also support diagnostic analyses and clinical workflows as well as patient monitoring & adherence to treatment. Dirk Sauer, Global Development Head of the Ophthalmology Franchise at Novartis Pharma AG, sees RetinAI as a strategic partner for advancing eye care through digital innovation: “With previous projects, RetinAI’s services have enabled us to enhance and more efficiently structure retina scans and data collected from our clinical studies. Together with RetinAI, we are working on end-to-end solutions to generate swift and comprehensive disease insights to better treat patients and improve patient outcomes.” RetinAI is excited to expand and intensify our partnership with Novartis who is one of the top pharma companies in ophthalmology with deep competence, dedication and focus on digital innovation in eye care. We clearly see the value that RetinAI can bring to Novartis. Our Discovery® platform and AI tools are enablers to increase efficiency in research and clinical studies and we expect they can also improve medications and treatments for patients. We believe using RetinAI’s technologies to support patients treated with ophthalmic medications will provide enhanced disease insights and create opportunities for more precise treatments." Dr. Carlos Ciller, CEO, RetinAI Source:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Retinai

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Retinai is included in 6 Expert Collections, including Artificial Intelligence ( AI ) in Healthcare.


Artificial Intelligence ( AI ) in Healthcare

826 items

These healthcare startups are using AI to discover new drugs, remotely monitor patients, securely transfer patient data, and more.


Eye Health

711 items


Artificial Intelligence

7,364 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

7,401 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.



5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,749 items

Retinai Patents

Retinai has filed 1 patent.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Computer vision
  • Feature detection (computer vision)
patents chart

Application Date

Grant Date


Related Topics



Image processing, Computer vision, Feature detection (computer vision), Artificial neural networks, Photographic techniques


Application Date


Grant Date


Related Topics

Image processing, Computer vision, Feature detection (computer vision), Artificial neural networks, Photographic techniques



Retinai Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Retinai Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.